In order to differentiate its flagship drug Opdivo® (nivolumab) amidst increasing competition, Bristol-Myers Squibb (BMS) has inked an alliance with Halozyme Therapeutics to develop subcutaneous formulations for upto 11 cancer immunotherapy targets. In return for providing access to its Enhanze® technology, Halozyme is entitled to US$105 M upfront and upto US$160 M in various milestones per target plus royalties and additional milestones for potential combinations. The Enhanze platform is based on recombinant human hyaluronidase, which aids in breaking down hyaluronan, a constituent sugar in the tumour microenvironment hindering drug absorption and dispersion.